This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEY
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $104.90, marking a -0.74% move from the previous day.
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
by Ekta Bagri
At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should First Trust NASDAQ-100 Ex-Technology Sector ETF (QQXT) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQXT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQEW
Gilead Sciences (GILD) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the preceding trading day.
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
by Zacks Equity Research
Sector ETF report for XBI
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for RSPH
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Gilead (GILD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Bayer's Vividion Initiates Dosing in Early-Stage Cancer Study
by Zacks Equity Research
BAYRY subsidiary Vividion Therapeutics doses the first patient in a phase I study on VVD-159642 to treat advanced solid tumors.
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
by Ritujay Ghosh
Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.
Stocks are Going on Sale, Time to be Greedy While Others are Fearful?
by Shaun Pruitt
History shows that buying stocks when they "go on sale" during a down period can be extremely rewarding for investors.
Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Gilead Sciences (GILD) reachead $112.39 at the closing of the latest trading day, reflecting a +0.45% change compared to its last close.
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS Study
by Zacks Equity Research
RHHBY's higher dose of multiple sclerosis drug Ocrevus did not meet its primary goal when compared to the approved 600 mg dose in relapsing multiple sclerosis patients.
FDA Grants Accelerated Approval to NVS Kidney Disease Drug
by Zacks Equity Research
Novartis strengthens its renal disease portfolio with accelerated approval of another drug for immunoglobulin A nephropathy.
Gilead Sciences (GILD) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the most recent trading session, Gilead Sciences (GILD) closed at $111.88, indicating a +0.54% shift from the previous trading day.